GlassScriptPhysician profile
Marvin Arnold Bishop
NPI 1578533766
$13,839.25
in general payments reported to CMS, 2019-2025
37 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $558 · 2021: $1,568 · 2022: $5,971 · 2023: $1,598 · 2024: $1,766 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,622 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,622.35 |
| Education | $252.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $4,813.68 | 2021-2024 | Lucemyra, Zimhi |
| Abbvie INC. | $3,581.96 | 2019-2025 | Skyrizi, Mavyret, Synthroid |
| Amgen INC. | $603.48 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $538.15 | 2021-2025 | Tremfya |
| Epi Health, LLC | $509.68 | 2020-2022 | |
| Pfizer INC. | $386.37 | 2021-2025 | |
| Indivior INC. | $378.45 | 2019-2025 | Sublocade |
| Regeneron Healthcare Solutions, INC. | $362.98 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $361.39 | 2022-2025 | Sotyktu |
| Mdd US Operations, LLC | $351.50 | 2019-2020 | |
| Genzyme Corporation | $350.42 | 2020-2022 | |
| Galderma Laboratories, L.P. | $316.77 | 2022-2024 | Aklief |
| Beta Bionics, INC. | $211.26 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ucb, INC. | $180.10 | 2023-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $157.50 | 2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $111.45 | 2025 | Freestyle Libre 3 |
| Pear Therapeutics (US), INC. | $86.37 | 2021 | |
| Medtronic, INC. | $66.62 | 2025 | Minimed 780g |
| Sensus Healthcare, INC. | $52.19 | 2021 | |
| Paratek Pharmaceuticals, INC. | $51.23 | 2025 | Nuzyra |
| Ascendis Pharma Endocrinology INC | $50.31 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $29.85 | 2024 | Strensiq |
| Leo Pharma INC. | $27.59 | 2023-2024 | Adbry |
| Mallinckrodt Hospital Products INC. | $27.02 | 2025 | Acthar |
| Lilly USA, LLC | $25.69 | 2020-2021 | |
| Kyowa Kirin, INC. | $24.54 | 2023 | |
| Radius Health, INC. | $24.08 | 2024 | Tymlos |
| Novo Nordisk INC | $20.39 | 2025 | Ozempic |
| Astellas Pharma US INC | $19.55 | 2024 | Veozah |
| Gilead Sciences, INC. | $19.54 | 2022 | |
| Corcept Therapeutics | $18.78 | 2022 | |
| Almirall LLC | $16.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.96 | 2025 | |
| Insulet Corporation | $14.58 | 2025 | Omnipod |
| Sun Pharmaceutical Industries INC. | $12.38 | 2019 | |
| Orexo US, INC. | $11.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.